







IMPLANTS BENCHMARKING ODEP & BEYOND COMPLIANCE

## KEITH TUCKER













## **DECLARATION OF INTERESTS**

Consultant Orthopaedic Surgeon. President BHS 2007-8

Chair Beyond Compliance advisory group and ODEP

Past Member NJR Steering Committee. Member NJR Implant performance committee,

In the past I received monies from J&J which were all paid into a research fund I hold stock in Accentus Medical

I do not receive any financial reward for NJR, MHRA BEYOND COMPLIANCE or ODEP work. My travel expenses are reimbursed.



#### WHAT DO WE MEAN BY A BENCHMARK?

Cosa si intende per un benchmark?

• Una norma concordata

- AN AGREED STANDARD
- AT A CERTAIN TIME POINT

 $\bullet$ 

- AGAINST WHICH ALL IMPLANTS ARE
   JUDGED
- THE BENCHMARK IS THE MINIMUM ACCEPTABLE STANDARD BASED ON THE NON INFERIORITY CONCEPT

- NB. THEY MUST ALL BE JUDGED IN EXACTLY THE SAME WAY
- IT IS NOT A COMPETITION

- A un certo punto nel tempo
- Contro cui tutti gli impianti sono giudicate
- Il benchmark è lo standard minimo accettabile sulla base di la non inferiorità concetto
- NB. Tutti devono essere giudicati esattamente
- NELLO STESSO MODO IN CUI
   NON SI TRATTI DI UN CONCORSO



### WHAT DO WE MEAN BY THE WORD BENCHMARK? Che cosa si intende con la parola benchmark?

**GUNS!** 



- The term benchmark, originates from the history of guns and ammunition, in regards to the same aim
- Il termine di benchmark, proviene dalla storia delle armi da fuoco e munizioni, in merito allo stesso scopo

## **IN A NUTSHELL**



## THAT MANUFACTURERS HAVE TO PRODUCE DATA (AT THEIR EXPENSE) TO SUPPORT THE USE OF THEIR IMPLANT



#### ENSURES THAT ALL NEW PRODUCTS ARE CAREFULLY MONITORED

### THEIR ORIGINS

BOTH ODEP AND BEYOND COMPLIANCE
 EVOLVED FROM DISASTERS





FROM METAL ON METAL DISASTERS

Protecting Patients, Supporting Innovation

# **ODEP..... OUR AIMS**



TO INFORM SURGEONS ABOUT THR PERFORMANCE OF
 INDIVIDUAL IMPLANTS

• TO REDUCE THE NUMBER OF REVISIONS

• TO IMPROVE PATIENT SAFETY

• IT IS NOT ABOUT PROCUREMENT OR COST





- MANUFACTURERS TO SUBMIT DATA TO SUPPORT THE CONTINUING USE OF THEIR PRODUCT
- ODEP ASSESS THE SUBMISSION AND AWARD "BENCHMARKS" ON THE BASIS OF MANUFACTURER'S DATA
- BENCHMARKS ARE AT 3,5,7,10 AND NOW 13 YEARS
- THE NUMBER REPRESENTS THE YEARS OF USE AND THE LETTER THE STRENGTH OF
  THE EVIDENCE
- THE IMPLANT HAS TO KEEP MOVING FROM ONE BENCHMARK TO THE NEXT





- REGISTRY DATA. MANUFACTURERS USE DATA FROM >12 WORLD WIDE REGISTRIES INCLUDING RIPO
- RCTS
- PEER REVIEWED PUBLICATIONS OR PRESENTATIONS (Our desire is to encourage local studies etc)
- VALIDATED IN HOUSE DATA

Criteria - A* Ratings	3A*	5A*	7A*	10A*	13A*
Minimum number of centres outside development centre(s)	3	3	3	3	3
Minium number of surgeons outside of development centre(s)	3	3	3	3	3
Minimum total cohort	150	250	350	500	500
Minimum at risk at benchmark time	150	225	300	400	400
Maximum revision rate ‡	3.0%	3.5%	4.0%	5.0%	6.5%
Criteria - A Ratings	3A	5A	7A	10A	13A
Minimum number of centres and surgeons	3	3	3	3	3
Minimum total cohort	150	250	350	500	500
Minimum at risk at benchmark time	72	66	60	51	42
Maximum revision rate ‡	5.0%	5.5%	6.0%	7.0%	8.5%
‡ The upper 95% confidence interval for KM revision rate (1 - Survival) must be lower than the specified level					
Criteria - B Ratings	3B	5B	7B	10B	13B
Minimum number of centres and surgeons	1	1	1	1	1
Minimum total cohort	100	100	100	100	100
Minimum at risk at benchmark time	40	40	40	40	40
Maximum value of 95% lower confidence limit for revision rate	3.0%	3.5%	4.0%	5.0%	6.5%
Criteria - Pre-Entry A*					
Product launched under Beyond Compliance					
Pre-Entry					
Products registered with NJR.					

#### **Criteria - Total Knee Replacement**



Criteria - A* Ratings	3A*	5A*	7A*	10A*	13A*
Minimum number of centres outside development centre(s)	3	3	3	3	3
Minimum number of surgeons outside of the development centre	3	3	3	3	3
Minimum total cohort	150	250	350	500	500
Minimum at risk at benchmark time	150	225	300	400	400
Maximum revision rate ‡	3.5%	4.0%	4.5%	5.0%	6.0%

Criteria - A Ratings	3A	5A	7A	10A	13A
Minimum number of centres and surgeons	3	3	3	3	3
Minimum total cohort	150	250	350	500	500
Minimum at risk at benchmark time	66	60	55	51	45
Maximum revision rate ‡	5.5%	6.0%	6.5%	7.0%	8.0%
‡ The upper 95% confidence interval for KM revision rate (1 - Su	irvival) m	lust be lov	wer than t	the specif	ied level

Criteria - B Ratings	3B	5B	7B	10B	13B
Minimum number of centres and surgeons	1	1	1	1	1
Minimum total cohort	100	100	100	100	100
Minimum at risk at benchmark time	40	40	40	40	40
Maximum value of 95% lower confidence limit for revision rate	3.5%	4.0%	4.5%	5.0%	6.0%



#### WHO USES US?



- ALL THE BIG 5 PLUS MOST OF THE WORLDS IMPLANT MANUFACTURERS
- LIMA, ADDLER, MEDACTA, CONFORMIS SYMBIOS, LINK ETC
- INDIAN AND CHINESE MANUFACTURERS
- THE IMPLANTS DO NOT HAVE TO BE SOLD IN THE UK MARKET TO BE BENCHMARKED BY ODEP


# ODEP 2002-2019



- Approximately 50 submissions for each meeting
- 25% go to appeal
- ~10% fail
- WITHDRAWN FROM THE MARKET 120



Hits on ODEP website <u>odep.org.uk</u> from 2015 to 2019 73,637 users, 127,780 sessions



Users by location: **UK – 43%** Rest of the world – **57%** <u>Top 10 countries</u> UK USA **Netherlands** Italy Germany India France Switzerland Spain Japan





## MONITORING

### THE INTRODUCTION OF NEW DEVICES OR MODIFICATION OF EXISTING ONES

# **"BEYOND COMPLIANCE"**

## "PROTECTING PATIENTS...... SUPPORTING INNOVATION"




Association of British Healthcare Industries



#### THE DISASTERS OF METAL ON METAL





Years since primary

Number at risk

- MoP	293,839	265,287	237,235	208,951	180,428	153,720	128,564	106,303	86,347	67,944	50,547	34,395	21,847	11,229	3,832
— MoM	1,108	1,087	1,057	1,026	982	940	884	823	759	654	472	306	169	73	13
- CoP	38,128	33,002	28,230	23,692	19,532	15,896	12,697	10,084	7,839	5,978	4,337	2,998	1,835	887	250

WHY "BEYOND COMPLIANCE?



- THE CE MARK IS COMPLIANCE
- ABOUT 7 YEARS AGO, OUT OF FRUSTRATION, WE THOUGHT IT WAS ABOUT TIME WE WENT "BEYOND COMPLIANCE"
- IN VIGILANCE
- IN DILIGENCE
- IT IS VOLUNTARY BUT UPLOADING INTO NJR IN THE UK IS COMPULSORY
- IT IS INDEPENDENT



- RISK ASSESSMENT
- DATA COLLECTION
- REVIEWS
- USER GROUP MEETINGS

• WE ARE INDEPENDENT AND THE SURGEONS ARE UNPAID...... NO CONFLICTS





#### **LEVEL 1 RISK** *NO MAJOR CHANGE FROM BENCHMARK PREDICATE OR EQUIVALENT*

### **LEVEL 2 RISK** ONE MAJOR CHANGE FROM BENCHMARK PREDICATE / EQUIVALENT


**LEVEL 3 RISK** 2 SIGNIFICANT CHANGES FROM BENCHMARK PREDICATE/EQUIVALENT Rate of introduction:- Limited Monitoring:- Full BC programme




## LEVEL 4 RISK

PAUCITY OF BENCHMARK DATA, > 3 MAJOR CHANGES FROM THE PREDICATE / EQUIVALENT Rate of Introduction:- Limited Monitoring:- Close monitoring

LEVEL 5 RISK WHERE A SIMILAR PRODUCT HAS FAILED *Rate of Introduction:-* Limited *Monitoring:-* Close monitoring



#### THE COLLECTION SYSTEM





## **REVIEWS**


(USUALLY 8PM ON A MONDAY EVENING)

CHAMPION SURGEON (S) MANUFACTURER NORTHGATE BC RAPPORTEURS

#### A REPORT FOR A REVIEW (DUMMY)

#### **BASIC DATA**

#### DEMOGRAPHICS




Total Procedures	110	931,111
Total Patients	106	765,348
Demographics		
Mean age	64.4	70.1
< 50	0.9%	1.8%
50 - 59	28.2%	11.2%
60 - 69	39.1%	32.5%
70 – 79	30.0%	38.5%
≥ 80	1.8%	16.1%
Median BMI	30	30
% BMI information available	94.5%	59.7%
Underweight (BMI < 18.5)	0.0%	0.3%
Normal (18.5 ≤ BMI < 25)	20.2%	10.1%
Overweight (25 ≤ BMI < 30)	26.0%	34.2%
Obese I (30 ≤ BMI < 35)	36.5%	32.3%
Obese II (35 ≤ BMI < 40)	11.5%	16.2%
Obese III (BMI≥40)	5.8%	6.9%
% Male	42.7%	42.6%
ASA Grades		
P1 - Fit and healthy	34.5%	11.1%
P2 - Mild disease not incapacitating	59.1%	72.4%
P3 - Incapacitating systemic disease	6.4%	16.1%
P4 / P5	0.0%	0.4%
Indications		
Osteoarthritis	100.00%	97.30%
Rheumatoid Arthritis	0.00%	1.64%
Other Inflammatory Arthropathy	0.00%	0.65%
Previous Trauma	0.00%	0.55%
Avascular Necrosis	0.00%	0.33%
Other	0.00%	0.37%

#### A REPORT FOR A REVIEW (DUMMY)

#### PERFORMANCE OF SURGEONS USING THE PROSTHESIS

#### **REASONS FOR REVISION**

Reason for Revision	Revised <sup>†</sup>	Expected Revisions*	p valı
Infection	0	0.34	1
Progressive Arthritis Remaining	0	0.06	1
Aseptic Loosening Femur	0	0.07	1
Aseptic Loosening Tibia	0	0.17	1
Aseptic Loosening Patella	0	0.04	1
Pain	1	0.21	0.192
Stiffness	0	0.13	1
Malalignment	0	0.11	1
Instability	2	0.19	0.017
Dislocation / Subluxation	0	0.04	1
Periprosthetic Fracture	0	0.03	1
Wear of Polyethylene Component	0	0.02	1
Lysis - Tibia	0	0.04	1
Lysis - Femur	0	0.02	1
Component Dissociation	0	0.01	1
Implant Fracture	0	0.00	1
Other / Not recorded	0	0.09	1
Total Revised	2	1.21	0.34



Each circle represents one surgeon. Red circles represent surgeons with a higher than expected revision rate (p < 0.001, and blue circles represent surgeons with a lower than expected revision rate (p < 0.001). Note that these rates have not been adjusted for case mix, or for variants of implant chosen.

# USER GROUP MEETINGS

Riunioni del gruppo di utilizzatori

#### AT BOA CONGRESS, EFFORT BHS, BASK

CHAMPION SURGEON(S) MANUFACTURER NORTHGATE BC RAPPORTEURS

PLUS ALL THOSE SURGEONS WHO ARE USING OR WHO MIGHT USE THE IMPLANT A BOA CONGRESS, EFORT BHS, BASK Champion chirurgo(s) Costruttore NORTHGATE BC relatori

E tutti i chirurghi che stanno utilizzando o chi potrebbe utilizzare l'impianto





## THE NEW EUROPEAN MDR



## WE ARE WORKING WITH BRUSSELS

NEW PRODUCTS =



## LEGACY PRODUCTS =

ODEP Orthopaedic Data Evaluation Panel





## RIAP / NJR / EPRD

# SHORTLY RIAP, NJR AND EPRD WILL BE SHARING THE SAME VERY COMPREHENSIVE DATABASE

#### YOUR REGISTRIES SHOULD SUPPLY **YOUR** MANUFACTURERS WITH YOUR DATA

#### FOR **YOU** TO ODEP BENCHMARK IN ITALY

#### TO INCREASE THE SAFETY OF **YOUR** PATIENTS

TO PROMOTE THEIR GOOD PRODUCTS





## FOR ITALY

### ODEP & OLTRE LA CONFORMITÀ PER L'ITALIA

#### YOU WILL NEED:

- SURGEON COMPLIANCE
- A GOOD REGISTRY
- COMPLETENESS OF REGISTRIES
- A COMMITTED TEAM
- YOU HAVE A TEAM
- WE CAN WORK WITH YOU

#### HAI BISOGNO

- Il chirurgo la conformità
- di un registro di buoni
- la completezza dei registri
- un team impegnato
- AVETE UN TEAM
- possiamo lavorare con voi



## THANK YOU FOR YOUR ATTENTION

#### **"PROTECTING PATIENTS......**

### SUPPORTING INNOVATION"



## ACKNOWLEDGEMENTS



- ALL THE PATIENTS WHO ALLOW US TO USE THEIR DATA
- BC AND ODEP SURGEONS
- TIM WILTON AND THE NJR
- THE TEAM AT NORTHGATE INCLUDING EDD CATON, RICHARD ARMSTRONG, PATRICK PALMER AND OLGA TAYLOR

